Roche Pegasys (correction)
Executive Summary
Roche plans to submit analysis of markers of interferon activity in patients on Pegasys (peginterferon alfa-2a) combination therapy within six months of European approval. The company does not have an official postmarketing commitment to study individualized dosing (1"The Pink Sheet" July 22, p. 17)...
You may also be interested in...
Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Roche will study individualized dosing regimens for Pegasys (peginterferon alfa-2a) in combination with ribavirin as part of its postmarketing commitments in Europe
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.